ORIC
vs
S&P 500
ORIC
S&P 500
Over the past 12 months, ORIC has significantly outperformed S&P 500, delivering a return of +45% compared to S&P 500's +19% growth.
Stocks Performance
ORIC vs S&P 500
Performance Gap
ORIC vs S&P 500
Performance By Year
ORIC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oric Pharmaceuticals Inc
Glance View
ORIC Pharmaceuticals is a clinical-stage drug developer focused on medicines for cancer and other serious diseases. Its main job is to discover and test new small-molecule therapies that target the biological pathways tumors use to grow, survive treatment, and become resistant to existing drugs. The company does not sell a broad portfolio of approved products. Instead, it advances drug candidates through preclinical work and clinical trials, and it may earn money in the future through product sales, licensing deals, or partnerships if any of its programs succeed. Its customers, in the broad sense, are patients and the doctors and hospitals that would use its medicines, while pharmaceutical partners are important to how it funds and develops its pipeline. ORIC stands out as a specialty biotech that tries to find weaknesses in cancer resistance biology rather than compete as a large commercial drug maker. That makes it an upstream part of the healthcare value chain: it takes scientific ideas from the lab into human testing, with the goal of creating new treatments that other companies, doctors, and health systems can eventually use.
